title: Stevens-Johnson syndrome after treatment with STI571: a case report.
abstract: Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.
authors.affiliation: Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan.
authors.forename: Liang-Tsai
authors.initials: LT
authors.lastname: Hsiao
authors.forename: Hung-Ming
authors.initials: HM
authors.lastname: Chung
authors.forename: Jen-Tsun
authors.initials: JT
authors.lastname: Lin
authors.forename: Tzeon-Jye
authors.initials: TJ
authors.lastname: Chiou
authors.forename: Jin-Hwang
authors.initials: JH
authors.lastname: Liu
authors.forename: Frank S
authors.initials: FS
authors.lastname: Fan
authors.forename: Wei-Shu
authors.initials: WS
authors.lastname: Wang
authors.forename: Chueh-Chuan
authors.initials: CC
authors.lastname: Yen
authors.forename: Po-Min
authors.initials: PM
authors.lastname: Chen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D003875:Drug Eruptions / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases